• Biodesix Relocates to Boulder, CO

    February 22, 2012 Biodesix, Inc., a fully integrated molecular diagnostics company dedicated to personalizing medicine, today announced the relocation of their corporate headquarters from Broomfield, Colorado to Boulder, Colorado. The new location at 2970 Wilderness Place, Suite 100, Boulder, CO 80301 will be able to accommodate Company’s future growth. Biodesix Research & Development locations, as well as the ... Read more
  • Biodesix Receives New EU and US Patents for Blood-based Oncology Tests

    January 30, 2012 Biodesix, Inc., a fully integrated molecular diagnostics company dedicated to personalizing medicine, today announced the issuance of three additional patents.  The U.S. Patent & Trademark Office (PTO) granted two new patents which provide intellectual property protection for methods relating to the Company’s products and technology. In addition, the European Patent Office granted to Biodesix a patent providing coverage ... Read more
  • VeriStrat® Test Predicts Outcomes in Advanced Breast Cancer Patients

    December 7, 2011 Results from the VeriStrat retrospective analysis of the Phase III trial, EGF30008, were presented today at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium. The EGF30008 study compared Femara® plus placebo to Femara plus Tykerb® in 1st line, hormone receptor positive, advanced breast cancer patients. The study included both Her2 positive and Her2 negative patients. Results ... Read more
  • Biodesix Receives 2011 North American Cancer Diagnostics Product Differentiation Excellence Award

    December 5, 2011 Biodesix Inc. a fully integrated molecular diagnostic company dedicated to personalizing medicine, is pleased to be the recipient of Frost & Sullivan’s 2011 North American Cancer Diagnostics Product Differentiation Excellence Award. The Product Differentiation Excellence Award is a prestigious recognition of Biodesix’ accomplishments in the cancer diagnostics industry, and of their first product, VeriStrat®. VeriStrat is a serum proteomic test ... Read more
  • Biodesix Announces New VeriStrat® Data to be Presented at the 34th Annual CTRC-AACR San Antonio Breast Cancer Symposium

    November 22, 2011 Biodesix today announced that results from a prospectively designed, retrospective analysis of serum samples from the phase III study, EGF30008, will be presented at the 34th Annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS). The purpose of the study was to evaluate the ability of the diagnostic test, VeriStrat, to predict patient outcomes following treatment with either ... Read more
  • Lung Cancer Study Evaluating Changes in VeriStrat Status over the Course of Treatment with Gefitinib Published in Journal of Thoracic Oncology

    November 2, 2011 Biodesix Inc, a fully integrated molecular diagnostic company dedicated to personalizing medicine, announced today the publication of “Changes in plasma mass-spectral (VeriStrat) profile in course of treatment of NSCLC patients with EGFR-TKIs” by Lazzari, et al. in the November issue of the Journal of Thoracic Oncology, currently available online. The study retrospectively evaluated VeriStrat classification prior to ... Read more
  • Biodesix to Present at BioConference Live – Innovative Online Conference

    October 24, 2011 ***Media Advisory*** WHAT: BioConference Live has selected Biodesix to present at the 5th annual Life Sciences conference, taking place online on October 26-27. Biodesix, based in Broomfield, CO, is a fully integrated molecular diagnostic company developing products for personalized medicine that improve clinical decision making. Paul Beresford, Biodesix Vice President, will discuss an alternative strategy for rapid companion diagnostic ... Read more
  • VeriStrat® Results Correlate with Survival Outcomes in Kidney Cancer Patients

    October 18, 2011 Data presented at the 10th International Kidney Cancer Symposium being held in Chicago, IL show that the pretreatment blood-based test, VeriStrat, was able to stratify renal cell carcinoma (RCC) patients treated with a combination of two targeted therapies, sunitinib (Sutent®) and erlotinib (Tarceva®), by survival outcomes. Patients who tested VeriStrat Good had significantly longer progression ... Read more
  • Biodesix to Work with Concentra and Hooper Holmes to Expand Access to VeriStrat®

    October 13, 2011 Biodesix Inc., a fully integrated molecular diagnostic company dedicated to personalizing medicine, today announced the initiation of two strategic partnerships that will provide cancer patients greater and more convenient options for completing VeriStrat testing. VeriStrat® is a blood-based test that helps physicians guide treatment for patients with non-small cell lung cancer (NSCLC). To increase the options available to patients ... Read more
  • Biodesix Selected to Present at Multi-State Investor and Partnering Conference

    September 27, 2011 WHAT: The Rocky Mountain Life Science Investor and Partnering Conference (RMLIPC) Selection Committee has chosen Biodesix to present to more than 50 national investors and partnering entities at its 2011 conference September 21-22 in Denver. Biodesix is one of 30 companies chosen to present at the regional conference held biennially by the Colorado BioScience Association (CBSA). Biodesix, based in Broomfield, ... Read more